Clindamycin Vaginal and Taurursodiol: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Clindamycin Vaginal
Taurursodiol
No brand names on recordHow we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Decreased exposure of the CYP3A4 substrate
Interaction Deep Dive
Concomitant use of sodium phenylbutyrate/taurursodiol (a CYP3A4 inducer) with a CYP3A4 substrate may result in decreased substrate exposure. Avoid use with CYP3A4 substrates where a small change in substrate plasma concentration may lead to serious toxicities or loss of efficacy1.
Why it happens (mechanism)
Induction of CYP3A4 substrate metabolism by sodium phenylbutyrate/taurursodiol
Common questions
Can I take Clindamycin Vaginal and Taurursodiol together?
Decreased exposure of the CYP3A4 substrate Always confirm with your pharmacist or prescriber before making any change.
How serious is the Clindamycin Vaginal and Taurursodiol interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Clindamycin Vaginal or Taurursodiol need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: RELYVRIO(TM) oral powder for suspension, sodium phenylbutyrate taurursodiol oral powder for suspension. Amylyx Pharmaceuticals Inc (per FDA), Cambridge, MA, 2022.
Keep reading about Clindamycin Vaginal
Keep reading about Taurursodiol
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist